EUCTR2019-004310-33-ES进行中（未招募）1 期
A Phase I Trial of Memory T Cells Expressing an ANTI-NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults with Advanced Sarcoma - CAR4SAR
Dr. Antonio Pérez Martínez0 个研究点目标入组 18 人开始时间: 2020年6月22日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age: < 30 years at the time of recurrence or progression with any type of sarcoma that has recurred or not responded to standard therapy and is deemed incurable by standard therapy.
- •Positive NKG2DL expression in sarcoma samples. Ideally, they should have centralized histological verification of NKG2DL expression in sarcoma samples (positive expression is defined as at least 2+ expression (0-4+ scale) in >50 percent of the tumor cells using anti-MICA and or anti-ULBP2). Patients will undergo biopsy following enrollment to obtain tissue to assess NKG2DL expression, with the following restrictions:
- •oIf the patient doesn´t have adequate accessible tumor for biopsy (at least 1 cm diameter).
- •oProcedures employed to acquire biopsies for tumor lysates will be limited to percutaneous needle or core biopsies, thoracoscopic excision or open biopsies of readily accessible lesions. Pulmonary lesions may be biopsied but extensive surgery such as thoracotomy or laparotomy should not be employed.
- •oPatients who require biopsy should not be enrolled if in the opinion of the principal investigator (PI), the tumor site places the patient at substantial related risk from the biopsy procedure.
- •In patients that fulfill any of these restrictions, when adequate archived tissue is available, this may be utilized to assess NKG2DL expression.
- •Patient must have either measurable or evaluable tumor.
- •The tumor must be accessible for intralesional administration of CAR T cells (only in ARM B).
- •Life expectancy of at least 10 weeks in opinion of the principal investigator (PI).
- •Lansky (age<16 years) or Karnofsky (age >=16 years) score of 50 or greater.
- •Patients must have recovered from the acute toxic effects of all prior anticancer therapy (including chemotherapy and radiotherapy).
- •Adequate bone marrow function defined by an absolute neutrophil count (ANC) of >/= 1.000/µL, platelet count of >/= 30.000/µL and hemoglobin of >/= 9.0 g/dl, and absence of a regular red blood cell and platelet transfusion requirement.
- •Patients should have a normal hepatic function with a total bilirubin <2 times the upper limit of normal and serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) < 2 times the upper limit of normal, and adequate renal function as defined by a serum creatinine = 1.5 upper limit of normal.
- •Patient or patient's legal representative, parent(s), or guardian able to provide written informed consent
- •Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the infusion. Male partner should use a condom.
- •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for at least 6 months after the NKG2D-CAR T infusion and until CAR-T cells are no longer present by qPCR on two consecutive tests. Highly effective contraception methods include:
- •oTotal abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (eg: calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
- •oUse of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that hav
排除标准
- •Enrolled in another treatment protocol
- •Evidence of untreated and active infection or clinically significant systemic illness:
- •oCardiac disorder defined as LVFE < 45% determined by ECHO.
- •oHuman Immunodeficiency Virus (HIV) positive test.
- •oPresence of active or prior CMV, EBV, hepatitis B or C as indicated by serology.
- •oAny significant pulmonary, hepatic or other organ dysfunction
- •Chronic corticosteroid dependence (except replacement therapy)
- •Evidence of any toxicity grade = 4 (according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.3)
- •Pregnant or lactating women.
- •Medical history of epilepsy.
- •Any other condition that, in the opinion if the PI, may interfere with the efficacy and/or safety evaluation of the trial.
研究者
相似试验
招募中
1 期
Trial to evaluate CAR-T NKG2D CAR cell infusions in patients with advanced sarcomaSarcomaCTIS2024-513514-35-00Hospital Universitario La Paz18
进行中（未招募）
1 期
A multicenter phase I/II study for the use of infusions of donor memory T cells after haploidentical stem cell transplantation with TCRaß and CD19-depleted stem cells.EUCTR2022-001080-27-DEniversity Hospital Tuebingen60
已完成
不适用
A pilot study to characterize T cell responses in young children after influenza infectio10047438influenzaNL-OMON33577niversitair Medisch Centrum Utrecht125
招募中
1 期
A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced SarcomaAdvanced SarcomaNCT06087341Antonio Pérez Martínez18
招募中
不适用
ImmuneCAP: Immune responses in severe community acquired pneumoniaSepsisACTRN12621001721897The George Institute for Global Health75